Protective effect of cyclic AMP against cisplatin-induced nephrotoxicity

Free Radical Biology and Medicine

Volumn 40, Issue 9, 2006, Pages 1564-1577

  Mishima, Kazuto ^a   Baba, Anri ^a   Matsuo, Misaki ^a   Itoh, Yoshinori ^a   Oishi, Ryozo ^a  

^a KYUSHU UNIVERSITY HOSPITAL   (Japan)

Author keywords

Cisplatin; Cyclic AMP; Free radicals; p38 mitogen activated protein kinase; Prostacyclin analogue; Reactive oxygen species; Renal tubular cell injury; Superoxide dismutase; Tumor necrosis factor

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 (4 FLUOROPHENYL) 2 (4 NITROPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ACETYLCYSTEINE; BERAPROST; BUCLADESINE; CISPLATIN; COPPER ZINC SUPEROXIDE DISMUTASE; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP DERIVATIVE; FORSKOLIN; GLUTATHIONE; ISOBUTYLMETHYLXANTHINE; LIPID; MANGANESE SUPEROXIDE DISMUTASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38; PROSTACYCLIN DERIVATIVE; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA;

ACUTE KIDNEY FAILURE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; IMMUNOCOMPETENT CELL; KIDNEY CELL CULTURE; KIDNEY INJURY; KIDNEY NECROSIS; KIDNEY TUBULE CELL; LIPID PEROXIDATION; MALE; NEPHROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CONTENT; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS INHIBITION; RAT; RENAL PROTECTION;

ACETYLCYSTEINE; ANIMALS; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; APOPTOSIS; CISPLATIN; CYCLIC AMP; ENZYME ACTIVATION; ENZYME INHIBITORS; EPOPROSTENOL; FLUORESCENT ANTIBODY TECHNIQUE; IN SITU NICK-END LABELING; LIPID PEROXIDATION; LIVER DISEASES; MALE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RATS; RATS, WISTAR; REACTIVE OXYGEN SPECIES; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR-ALPHA;

ANIMALIA;

EID: 33646066251     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2005.12.025     Document Type: Article

References (46)

1. Weiner M.W., and Jacobs C. Mechanism of cisplatin nephrotoxicity. Fed. Proc. 42 (1983) 2974-2978
2. Kuhlmann M.K., Burkhardt G., and Kohler H. Insights into potential cellular mechanisms of cisplatin nephrotoxicity and their clinical application. Nephrol. Dial. Transplant. 12 (1997) 2478-2480
3. Babu E., Gopalakrishnan V.K., Sriganth I.N., Gopalakrishnan R., and Sakthisekaran D. Cisplatin induced nephrotoxicity and the modulating effect of glutathione ester. Mol. Cell. Biochem. 144 (1995) 7-11
4. Matsushima H., Yonemura K., Ohishi K., and Hishida A. The role of oxygen free radicals in cisplatin-induced acute renal failure in rats. J. Lab. Clin. Med. 131 (1998) 518-526
5. Sueishi K., Mishima K., Makino K., Itoh Y., Tsuruya K., Hirakata H., and Oishi R. Protection by a radical scavenger edaravone against cisplatin-induced nephrotoxicity in rats. Eur. J. Pharmacol. 451 (2002) 203-208
6. Kruidering M., Van de Water B., de Heer E., Mulder G.J., and Nagelkerke J.F. Cisplatin-induced nephrotoxicity in porcine proximal tubular cells: mitochondrial dysfunction by inhibition of complexes I to IV of the respiratory chain. J. Pharmacol. Exp. Ther. 280 (1997) 638-649
7. 2+ in cisplatin-induced cell injury in rabbit renal cortical slices. Toxicol. Appl. Pharmacol. 146 (1997) 261-269
8. Schaaf G.J., Maas R.F., de Groene E.M., and Fink-Gremmels J. Management of oxidative stress by heme oxygenase-1 in cisplatin-induced toxicity in renal tubular cells. Free Radic. Res. 36 (2002) 835-843
9. Lieberthal W., Triaca V., and Levine J. Mechanisms of death induced by cisplatin in proximal tubular epithelial cells: apoptosis vs. necrosis. Am. J. Physiol. 270 (1996) F700-F708
10. Lau A.H. Apoptosis induced by cisplatin nephrotoxic injury. Kidney Int. 56 (1999) 1295-1298
11. Cummings B.S., and Schnellmann R.G. Cisplatin-induced renal cell apoptosis: caspase 3-dependent and -independent pathways. J. Pharmacol. Exp. Ther. 302 (2002) 8-17
12. Park M.S., De Leon M., and Devarajan P. Cisplatin induces apoptosis in LLC-PK1 cells via activation of mitochondrial pathways. J. Am. Soc. Nephrol. 13 (2002) 858-865
13. Shino Y., Itoh Y., Kubota T., Sendo T., and Oishi R. Role of poly(ADP-ribose) polymerase in cisplatin-induced injury in LLC-PK1 cells. Free Radic. Biol. Med. 35 (2003) 966-977
14. Ramesh G., and Reeves W.B. TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J. Clin. Invest. 110 (2002) 835-842
15. Ramesh G., and Reeves W.B. TNFR2-mediated apoptosis and necrosis in cisplatin-induced acute renal failure. Am. J. Physiol. Renal Physiol. 285 (2003) F610-F618
16. Ramesh G., and Reeves W.B. p38 MAP kinase inhibition ameliorates cisplatin nephrotoxicity in mice. Am. J. Physiol. Renal Physiol. 289 (2005) F166-F174
17. 2-adrenoceptor prevents shiga toxin 2-induced TNF-α gene transcription. J. Am. Soc. Nephrol. 12 (2001) 2288-2299
18. 2-Adrenoceptor agonist suppresses tumour necrosis factor production in rat mesangial cells. Cytokine 12 (2000) 491
19. Zhang L.M., Castresana M.R., Shaker I.J., Dalton M.L., Leeper-Woodford S.K., and Newman W.H. Increased intracellular cyclic adenosine 3′, 5′-monophosphate inhibits release of tumor necrosis factor-α from human vascular tissue and cultured smooth muscle cells. Crit. Care Med. 25 (1997) 1855-1861
20. Newman W.H., Zhang L.M., Lee D.H., Dalton M.L., Warejcka D.J., Castresana M.R., and Leeper-Woodford S.K. Release of tumor necrosis factor-α from coronary smooth muscle: activation of NF-κB and inhibition by elevated cyclic AMP. J. Surg. Res. 80 (1998) 129-135
21. Chong Y.H., Shin S.A., Lee H.J., Kang J.H., and Suh Y.H. Molecular mechanisms underlying cyclic AMP inhibition of macrophage dependent TNF-α production and neurotoxicity in response to amyloidogenic C-terminal fragment of Alzheimer's amyloid precursor protein. J. Neuroimmunol. 133 (2002) 160-174
22. Bai Y., Suzuki A.K., and Sagai M. The cytotoxic effects of diesel exhaust particles on human pulmonary artery endothelial cells in vitro: role of active oxygen species. Free Radic. Biol. Med. 30 (2001) 555-562
23. Kubota T., Fujisaki K., Itoh Y., Yano T., Sendo T., and Oishi R. Apoptotic injury in cultured human hepatocytes induced by HMG-CoA reductase inhibitors. Biochem. Pharmacol. 67 (2004) 2175-2186
24. Takahashi M., Shibatam M., and Niki E. Estimation of lipid peroxidation of live cells using a fluorescent probe, diphenyl-1-pyrenylphosphine. Free Radic. Biol. Med. 31 (2001) 164-174
25. Senator A., Rachidi W., Lehmann S., Favier A., and Benboubetra M. Prion protein protects against DNA damage induced by paraquat in cultured cells. Free Radic. Biol. Med. 37 (2004) 1224-1230
26. Peskin A.V., and Winterbourn C.C. A microtiter plate assay for superoxide dismutase using a water-soluble tetrazolium salt (WST-1). Clin. Chim. Acta 293 (2000) 157-166
27. Preuss M., Girnun G.D., Darby C.J., Khoo N., Spector A.A., and Robbins M.E. Role of antioxidant enzyme expression in the selective cytotoxic response of glioma cells to gamma-linolenic acid supplementation. Free Radic. Biol. Med. 28 (2000) 1143-1156
28. Ingram A.J., James L., Thai K., Ly H., Cai L., and Scholey J.W. Nitric oxide modulates mechanical strain-induced activation of p38 MAPK in mesangial cells. Am. J. Physiol. Renal Physiol. 279 (2000) F243-F251
29. Chijiwa T., Mishima A., Hagiwara M., Sano M., Hayashi K., Inoue T., Naito K., Toshioka T., and Hidaka H. Inhibition of forskolin-induced neurite outgrowth and protein phosphorylation by a newly synthesized selective inhibitor of cyclic AMP-dependent protein kinase, N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide (H-89), of PC12D pheochromocytoma cells. J. Biol. Chem. 265 (1990) 5267-5272
30. Akasaka K., Suzuki T., Ohrui H., and Meguro H. Study on aromatic phosphines for novel fluorometry of hydroperoxides (II)-the determination of lipid hydroperoxides with diphenyl-1-pyrenylphosphine. Anal. Lett. 20 (1987) 797-807
31. Akasaka K., Ijichi S., Watanabe K., Ohrui H., and Meguro H. High-performance liquid chromatography and postcolumn derivatization with diphenyl-1-pyrenylphosphine for fluorometric determination of triacylglycerol hydroperoxides. J. Chromatogr. 596 (1992) 197-202
32. Nicolai S., Willems J., Zwijsen A., Van Mechelen E., and Slegers H. Cyclic AMP-induced differentiation increases the synthesis of extracellular superoxide dismutase in rat C6 glioma. Free Radic. Biol. Med. 21 (1996) 481-486
33. Adachi T., Yamada H., Hara H., Futenma A., and Kakumu S. Increase of urinary extracellular-superoxide dismutase level correlated with cyclic adenosine monophosphate. FEBS Lett. 458 (1999) 370-374
34. Yoshimoto T., Fukai N., Sato R., Sugiyama T., Ozawa N., Shichiri M., and Hirata Y. Antioxidant effect of adrenomedullin on angiotensin II-induced reactive oxygen species generation in vascular smooth muscle cells. Endocrinology 145 (2004) 3331-3337
35. Wong G.H., Elwell J.H., Oberley L.W., and Goeddel D.V. Manganous superoxide dismutase is essential for cellular resistance to cytotoxicity of tumor necrosis factor. Cell 58 (1989) 923-931
36. Yamakawa T., Eguchi S., Matsumoto T., Yamakawa Y., Numaguchi K., Miyata I., Reynolds C.M., Motley E.D., and Inagami T. Intracellular signaling in rat cultured vascular smooth muscle cells: roles of nuclear factor-κB and p38 mitogen-activated protein kinase on tumor necrosis factor-α production. Endocrinology 140 (1999) 3562-3572
37. Nick J.A., Young S.K., Arndt P.G., Lieber J.G., Suratt B.T., Poch K.R., Avdi N.J., Malcolm K.C., Taube C., Henson P.M., and Worthen G.S. Selective suppression of neutrophil accumulation in ongoing pulmonary inflammation by systemic inhibition of p38 mitogen-activated protein kinase. J. Immunol. 169 (2002) 5260-5269
38. Nick J.A., Avdi N.J., Young S.K., Lehman L.A., McDonald P.P., Frasch S.C., Billstrom M.A., Henson P.M., Johnson G.L., and Worthen G.S. Selective activation and functional significance of p38(mitogen-activated protein kinase in lipopolysaccharide-stimulated neutrophils. J. Clin. Invest. 103 (1999) 851-858
39. Chong Y.H., Shin S.A., Lee H.J., Kang J.H.L., and Suh Y.H. Molecular mechanisms underlying cyclic AMP inhibition of macrophage dependent TNF-α production and neurotoxicity in response to amyloidogenic C-terminal fragment of Alzheimer's amyloid precursor protein. J. Neuroimmunol. 133 (2002) 160-174
40. Yoon S.W., Goh S.H., Chun J.S., Cho E.W., Lee M.K., Kim K.L., Kim J.J., Kim C.J., and Poo H. α-Melanocyte-stimulating hormone inhibits lipopolysaccharide-induced tumor necrosis factor-α production in leukocytes by modulating protein kinase A, p38 kinase, and nuclear factor κB signaling pathways. J. Biol. Chem. 278 (2003) 32914-32920
41. Won J.S., Im Y.B., Singh A.K., and Singh I. Dual role of cAMP in iNOS expression in glial cells and macrophages is mediated by differential regulation of p38-MAPK/ATF-2 activation and iNOS stability. Free Radic. Biol. Med. 37 (2004) 1834-1844
42. Feng W.G., Wang Y.B., Zhang J.S., Wang X.Y., Li C.L., and Chang Z.L. cAMP elevators inhibit LPS-induced IL-12 p40 expression by interfering with phosphorylation of p38 MAPK in murine peritoneal macrophages. Cell Res. 12 (2002) 331-337
43. Rahman A., Anwar K.N., Minhajuddin M., Bijli K.M., Javaid K., True A.L., and Malik A.B. cAMP targeting of p38 MAP kinase inhibits thrombin-induced NF-κB activation and ICAM-1 expression in endothelial cells. Am. J. Physiol. Lung Cell Mol. Physiol. 287 (2004) L1017-L1024
44. Melian E.B., and Goa K.L. Beraprost: a review of its pharmacology and therapeutic efficacy in the treatment of peripheral arterial disease and pulmonary arterial hypertension. Drugs 62 (2002) 107-133
45. Akiba T., Miyazaki M., and Toda N. Vasodilator actions of TRK-100, a new prostaglandin I2 analogue. Br. J. Pharmacol. 89 (1986) 703-711
46. 2 analogue mitigates the progression rate of renal dysfunction improving renal blood flow without glomerular hyperfiltration in patients with chronic renal insufficiency. Prostaglandins Leukotrienes Essent. Fatty Acids 65 (2001) 223-227